Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer's disease

Neuropharmacology

Volumn 56, Issue 4, 2009, Pages 808-813

  Bourasset, Fanchon ^a   Ouellet, Mélissa ^b   Tremblay, Cyntia ^b   Julien, Carl ^b   Do, Tuan Minh ^a   Oddo, Salvatore ^c   LaFerla, Frank ^c   Calon, Frédéric ^b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

3 Tg AD; Alzheimer; Blood brain barrier; Brain perfusion; Collagen; Vascular pathology

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CARBON 14; COLLAGEN; DIAZEPAM; GLUCOSE; INULIN; SUCROSE; TAU PROTEIN; TRITIUM;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; BRAIN PERFUSION; BRAIN SIZE; CEREBELLUM; CONTROLLED STUDY; FRONTAL CORTEX; HIPPOCAMPUS; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BASEMENT MEMBRANE; BLOOD VESSELS; BRAIN; BRAIN CHEMISTRY; CEREBROVASCULAR CIRCULATION; COLLAGEN TYPE I; COLLAGEN TYPE IV; DIAZEPAM; GABA MODULATORS; GLUCOSE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, TRANSGENIC; TAU PROTEINS;

EID: 60349096101     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.01.006     Document Type: Article

References (41)

1. Beckmann N., Schuler A., Mueggler T., Meyer E.P., Wiederhold K.H., Staufenbiel M., and Krucker T. Age-dependent cerebrovascular abnormalities and blood flow disturbances in APP23 mice modeling Alzheimer's disease. J. Neurosci. 23 (2003) 8453-8459
2. Bornstein P., and Sage H. Structurally distinct collagen types. Annu. Rev. Biochem. 49 (1980) 957-1003
3. Bouras C., Kovari E., Herrmann F.R., Rivara C.B., Bailey T.L., von Gunten A., Hof P.R., and Giannakopoulos P. Stereologic analysis of microvascular morphology in the elderly: Alzheimer disease pathology and cognitive status. J. Neuropathol. Exp. Neurol. 65 (2006) 235-244
4. Bourasset F., Cisternino S., Temsamani J., and Scherrmann J.M. Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier. J. Neurochem. 86 (2003) 1564-1567
5. Bradley K.M., O'Sullivan V.T., Soper N.D., Nagy Z., King E.M., Smith A.D., and Shepstone B.J. Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer's disease. Brain 125 (2002) 1772-1781
6. Buee L., Hof P.R., Bouras C., Delacourte A., Perl D.P., Morrison J.H., and Fillit H.M. Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders. Acta Neuropathol. (Berl.) 87 (1994) 469-480
7. Castellani R.J., Smith M.A., Perry G., and Friedland R.P. Cerebral amyloid angiopathy: major contributor or decorative response to Alzheimer's disease pathogenesis. Neurobiol. Aging 25 (2004) 599-602
8. Cummings J.L., Silverman D., Small G., and Phelps M. The role of positron emission tomography in the diagnosis of Alzheimer's disease. J. Am. Geriatr. Soc. 52 (2004) 467-468 author reply 468-469
9. Dagenais C., Rousselle C., Pollack G.M., and Scherrmann J.M. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. J. Cereb. Blood Flow Metab. 20 (2000) 381-386
10. Garcia-Alloza M., Robbins E.M., Zhang-Nunes S.X., Purcell S.M., Betensky R.A., Raju S., Prada C., Greenberg S.M., Bacskai B.J., and Frosch M.P. Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis. 24 (2006) 516-524
11. Hawkins B.T., and Egleton R.D. Pathophysiology of the blood-brain barrier: animal models and methods. Curr. Top. Dev. Biol. 80 (2008) 277-309
12. Herzig M.C., Van Nostrand W.E., and Jucker M. Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models. Brain Pathol. 16 (2006) 40-54
13. Hooijmans C.R., Rutters F., Dederen P.J., Gambarota G., Veltien A., van Groen T., Broersen L.M., Lutjohann D., Heerschap A., Tanila H., and Kiliaan A.J. Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched Typical Western Diet (TWD). Neurobiol. Dis. 28 (2007) 16-29
14. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat. Rev. Neurosci. 5 (2004) 347-360
15. Janelsins M.C., Mastrangelo M.A., Oddo S., LaFerla F.M., Federoff H.J., and Bowers W.J. Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J. Neuroinflammation 2 (2005) 23
16. Jellinger K.A., and Attems J. Prevalence and pathogenic role of cerebrovascular lesions in Alzheimer disease. J. Neurol. Sci. 229-230 (2005) 37-41
17. Johnson N.A., Jahng G.H., Weiner M.W., Miller B.L., Chui H.C., Jagust W.J., Gorno-Tempini M.L., and Schuff N. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 234 (2005) 851-859
18. Julien, C., Tremblay, C., Phivilay, A., Berthiaume, L., Emond, V., Julien, P., Calon, F. High-fat diet aggravates amyloid-beta and tau pathologies in the 3×Tg-AD mouse model. Neurobiol. Aging, in press, doi:10.1016/j.neurobiolaging.2008.08.022 [published on-line October 14, 2008].
19. Kalaria R.N. Small vessel disease and Alzheimer's dementia: pathological considerations. Cerebrovas. Dis. 13 Suppl. 2 (2002) 48-52
20. Kalaria R.N., and Pax A.B. Increased collagen content of cerebral microvessels in Alzheimer's disease. Brain Res. 705 (1995) 349-352
21. Khachaturian A.S., Zandi P.P., Lyketsos C.G., Hayden K.M., Skoog I., Norton M.C., Tschanz J.T., Mayer L.S., Welsh-Bohmer K.A., and Breitner J.C. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch. Neurol. 63 (2006) 686-692
22. Lee G.D., Aruna J.H., Barrett P.M., Lei D.L., Ingram D.K., and Mouton P.R. Stereological analysis of microvascular parameters in a double transgenic model of Alzheimer's disease. Brain Res. Bull. 65 (2005) 317-322
23. Mueggler T., Sturchler-Pierrat C., Baumann D., Rausch M., Staufenbiel M., and Rudin M. Compromised hemodynamic response in amyloid precursor protein transgenic mice. J. Neurosci. 22 (2002) 7218-7224
24. Niwa K., Kazama K., Younkin L., Younkin S.G., Carlson G.A., and Iadecola C. Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. Am. J. Physiol. Heart Circ. Physiol. 283 (2002) H315-H323
25. Niwa K., Kazama K., Younkin S.G., Carlson G.A., and Iadecola C. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol. Dis. 9 (2002) 61-68
26. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., and LaFerla F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39 (2003) 409-421
27. Paris D., Humphrey J., Quadros A., Patel N., Crescentini R., Crawford F., and Mullan M. Vasoactive effects of Abeta in isolated human cerebrovessels and in a transgenic mouse model of Alzheimer's disease: role of inflammation. Neurol. Res. 25 (2003) 642-651
28. Paris D., Patel N., DelleDonne A., Quadros A., Smeed R., and Mullan M. Impaired angiogenesis in a transgenic mouse model of cerebral amyloidosis. Neurosci. Lett. 366 (2004) 80-85
29. Paris D., Quadros A., Humphrey J., Patel N., Crescentini R., Crawford F., and Mullan M. Nilvadipine antagonizes both Abeta vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. Brain Res. 999 (2004) 53-61
30. Paul J., Strickland S., and Melchor J.P. Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J. Exp. Med. 204 (2007) 1999-2008
31. Qutub A.A., and Hunt C.A. Glucose transport to the brain: a systems model. Brain Res. Brain Res. Rev. 49 (2005) 595-617
32. Rockenstein E., Adame A., Mante M., Larrea G., Crews L., Windisch M., Moessler H., and Masliah E. Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin?. J. Neural Transm. 112 (2005) 269-282
33. Schneider J.A., Arvanitakis Z., Bang W., and Bennett D.A. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69 (2007) 2197-2204
34. Scholz W. Studien zur Pathologie der Hirngefässe II; Die drusige Entartung der Hirnarterien und - capillaren. Neurol. Psychiatr. 162 (1938) 694-715
35. Thal, D.R., Capetillo-Zarate, E., Larionov, S., Staufenbiel, M., Zurbruegg, S., Beckmann, N. Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flow disturbances. Neurobiol. Aging, in press, doi:10.1016/j.neurobiolaging.2008.01.017 [published on-line March 21, 2008].
36. Tong X.K., Nicolakakis N., Kocharyan A., and Hamel E. Vascular remodeling versus amyloid beta-induced oxidative stress in the cerebrovascular dysfunctions associated with Alzheimer's disease. J. Neurosci. 25 (2005) 11165-11174
37. Tremblay C., Pilote M., Phivilay A., Emond V., Bennett D.A., and Calon F. Biochemical characterization of Abeta and tau pathologies in mild cognitive impairment and Alzheimer's disease. J. Alzheimers Dis. 12 (2007) 377-390
38. Ujiie M., Dickstein D.L., Carlow D.A., and Jefferies W.A. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 10 (2003) 463-470
39. Wang H., Golob E.J., and Su M.Y. Vascular volume and blood-brain barrier permeability measured by dynamic contrast enhanced MRI in hippocampus and cerebellum of patients with MCI and normal controls. J. Magn. Reson. Imaging 24 (2006) 695-700
40. Zarow C., Barron E., Chui H.C., and Perlmutter L.S. Vascular basement membrane pathology and Alzheimer's disease. Ann. N. Y. Acad. Sci. 826 (1997) 147-160
41. Zlokovic B.V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci. 28 (2005) 202-208